Wegovy (semaglutide) is approved by the U.S. Food and Drug Administration (FDA) for weight loss and weight management in ...

As the popularity of GLP-1 medications to support weight loss in adults surges, it's not surprising that there's also been a ...

Novo Nordisk plans to initiate late-stage trials for its next-gen weight-loss drug amycretin in 2026. The trials will include ...

A recent study reveals a surge in the use of GLP-1 medications, such as Ozempic and Wegovy, among younger age groups.

Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...

"We recommend that any patients experiencing side effects while taking GLP-1 receptor agonists including Wegovy® (semaglutide ...

No drug is without potential side effects, and there are five major ones that people taking Ozempic, Wegovy or Mounjaro are ...